Compare Stocks: ABUS, CELC, CDNA, and IDYA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.22 -1.6%	$4.82	$3.50 ▼ $5.45	$836.01M	0.76	8.22 million shs	4.54 million shs
CDNA CareDx	$64.00 -4.0%	$55.03	$14.03 ▼ $72.51	$3.31B	2.38	1.56 million shs	1.50 million shs
CELC Celcuity	$56.58 -6.2%	$82.95	$49.80 ▼ $151.02	$2.77B	0.1	1.48 million shs	4.34 million shs
IDYA IDEAYA Biosciences	$32.85 -3.0%	$37.95	$26.81 ▼ $42.68	$2.89B	-0.04	955,709 shs	655,119 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	0.00%	-16.77%	-7.46%	-5.59%
CDNA CareDx	0.00%	+0.52%	+17.91%	+61.09%	+335.37%
CELC Celcuity	0.00%	-16.72%	-33.36%	-35.98%	+13.09%
IDYA IDEAYA Biosciences	0.00%	-9.03%	-14.92%	-8.78%	+15.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.22 -1.6%	$4.82	$3.50 ▼ $5.45	$836.01M	0.76	8.22 million shs	4.54 million shs
CDNA CareDx	$64.00 -4.0%	$55.03	$14.03 ▼ $72.51	$3.31B	2.38	1.56 million shs	1.50 million shs
CELC Celcuity	$56.58 -6.2%	$82.95	$49.80 ▼ $151.02	$2.77B	0.1	1.48 million shs	4.34 million shs
IDYA IDEAYA Biosciences	$32.85 -3.0%	$37.95	$26.81 ▼ $42.68	$2.89B	-0.04	955,709 shs	655,119 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	0.00%	-16.77%	-7.46%	-5.59%
CDNA CareDx	0.00%	+0.52%	+17.91%	+61.09%	+335.37%
CELC Celcuity	0.00%	-16.72%	-33.36%	-35.98%	+13.09%
IDYA IDEAYA Biosciences	0.00%	-9.03%	-14.92%	-8.78%	+15.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	18.48% Upside
CDNA CareDx	2.38	Hold	$54.00	-15.63% Downside
CELC Celcuity	2.69	Moderate Buy	$154.25	172.62% Upside
IDYA IDEAYA Biosciences	2.82	Moderate Buy	$52.36	59.38% Upside

Current Analyst Ratings Breakdown

Latest ABUS, CELC, CDNA, and IDYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	IDYA IDEAYA Biosciences	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	IDYA IDEAYA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	IDYA IDEAYA Biosciences	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$48.00
10/13/2026	CELC Celcuity	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/8/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C) ➝ Hold (C+)
10/2/2026	CDNA CareDx	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
9/30/2026	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$140.00 ➝ $134.00
9/24/2026	CDNA CareDx	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$60.00 ➝ $74.00
9/22/2026	IDYA IDEAYA Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/17/2026	CELC Celcuity	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$157.00
9/9/2026	IDYA IDEAYA Biosciences	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$54.00 ➝ $57.00

(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$181.72M	4.60	N/A	N/A	$0.40 per share	10.55
CDNA CareDx	$458.09M	7.23	$0.01 per share	9,825.90	$5.89 per share	10.87
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
IDYA IDEAYA Biosciences	$234.13M	12.33	N/A	N/A	$11.67 per share	2.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	5.34	N/A	N/A	84.22%	90.98%	82.34%	11/16/2026 (Estimated)
CDNA CareDx	-$21.35M	$2.07	30.92	101.59	N/A	24.23%	2.87%	2.17%	10/29/2026 (Confirmed)
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/9/2026 (Estimated)

Latest ABUS, CELC, CDNA, and IDYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	CELC Celcuity	-$1.45	N/A	N/A	N/A	$2.40 million	N/A
11/9/2026	Q3 2026	IDYA IDEAYA Biosciences	-$1.18	N/A	N/A	N/A	$7.12 million	N/A
10/29/2026	Q3 2026	CDNA CareDx	$0.2552	N/A	N/A	N/A	$121.95 million	N/A
8/13/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	81.42
CDNA CareDx	N/A	4.58	4.51
CELC Celcuity	6.04	8.93	8.93
IDYA IDEAYA Biosciences	N/A	10.45	10.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
CDNA CareDx	N/A
CELC Celcuity	63.33%
IDYA IDEAYA Biosciences	98.29%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
CDNA CareDx	2.40%
CELC Celcuity	13.33%
IDYA IDEAYA Biosciences	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	19	198.11 million	158.68 million	Optionable
CDNA CareDx	765	51.73 million	50.49 million	Optionable
CELC Celcuity	155	48.93 million	42.41 million	Optionable
IDYA IDEAYA Biosciences	145	87.86 million	83.73 million	Optionable

ABUS, CELC, CDNA, and IDYA Headlines

Recent News About These Companies

William Blair sets USD 51.00 target for IDEAYA Biosciences stock

October 17 at 8:11 PM | ad-hoc-news.deA

William Blair initiates coverage of IDEAYA Biosciences with outperform

October 16 at 10:17 PM | msn.com

William Blair Initiates Coverage on IDEAYA Biosciences With Outperform Rating

October 16 at 12:15 PM | marketscreener.comM

Stifel Nicolaus Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA)

October 16 at 1:36 AM | americanbankingnews.com

Stifel sets USD 48.00 target for IDEAYA Biosciences stock

October 15 at 8:29 PM | ad-hoc-news.deA

Stifel initiates coverage of IDEAYA Biosciences with buy

October 14, 2026 | msn.com

IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma

October 14, 2026 | seekingalpha.com

IDEAYA Biosciences (NASDAQ:IDYA) Now Covered by Analysts at Stifel Nicolaus

October 14, 2026 | marketbeat.com

IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock

October 11, 2026 | defenseworld.netD

Insider Selling: IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells 26,338 Shares of Stock

October 9, 2026 | insidertrades.com

IDEAYA Biosciences (NASDAQ:IDYA) Stock: Insider Yujiro Hata Sells 26,338 Shares

October 8, 2026 | marketbeat.com

IDEAYA Biosciences (NASDAQ:IDYA) vs. Sangamo Therapeutics (NASDAQ:SGMO) Head to Head Review

October 8, 2026 | americanbankingnews.com

IDEAYA Biosciences, Inc. $IDYA Holdings Lifted by Congress Asset Management Co.

October 8, 2026 | marketbeat.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Moderate Buy" from Analysts

October 4, 2026 | marketbeat.com

IDEAYA Biosciences stock reports Q2 revenue growth despite loss

October 1, 2026 | ad-hoc-news.deA

IDEAYA Biosciences (NASDAQ:IDYA) Shares Climb 4.8% - Here's Why

September 28, 2026 | marketbeat.com

IDEAYA promotes Michael White to R&D president

September 28, 2026 | grafa.comG

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

September 28, 2026 | prnewswire.com

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

September 25, 2026 | insidermonkey.com

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 25, 2026 | prnewswire.com

Bank of America Corp DE Buys New Stake in IDEAYA Biosciences, Inc. $IDYA

September 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, CELC, CDNA, and IDYA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$4.22 -0.07 (-1.63%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$4.22 +0.00 (+0.12%)

As of 10/16/2026 07:30 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

CareDx NASDAQ:CDNA

$64.00 -2.68 (-4.02%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$63.62 -0.38 (-0.59%)

As of 10/16/2026 07:56 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Celcuity NASDAQ:CELC

$56.58 -3.72 (-6.17%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$56.59 +0.01 (+0.02%)

As of 10/16/2026 07:30 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

IDEAYA Biosciences NASDAQ:IDYA

$32.85 -1.00 (-2.95%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$33.03 +0.18 (+0.55%)

As of 10/16/2026 07:45 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABUS, CELC, CDNA, and IDYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABUS, CELC, CDNA, and IDYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABUS, CELC, CDNA, and IDYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, CELC, CDNA, and IDYA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

CareDx NASDAQ:CDNA

Celcuity NASDAQ:CELC

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABUS, CELC, CDNA, and IDYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABUS, CELC, CDNA, and IDYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABUS, CELC, CDNA, and IDYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, CELC, CDNA, and IDYA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

CareDx NASDAQ:CDNA

Celcuity NASDAQ:CELC

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools